Literature DB >> 1886708

Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.

S Mashiyama1, Y Murakami, T Yoshimoto, T Sekiya, K Hayashi.   

Abstract

Single-strand conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP analysis) was used for detection of mutations of the p53 gene in surgical specimens of human brain tumors. Six of 45 brain tumors showed mobility shifts in the analyses. These six tumors also showed loss of a normal allele. The samples were examined further by direct sequencing. Results showed that four of them had single-base substitutions and the other two had deletions of one and eight base pairs. Five of the six mutations detected were clustered in highly conserved regions of the p53 gene. The frequency of p53 gene mutations in primary brain tumors examined was 9.8%. We also found two new polymorphic markers in the p53 gene, one in intron 7 and the other in an Alu repeat in exon 11. Both markers could be detected by SSCP analysis. Using these two markers, we found two cases of loss of heterozygosity in other brain tumor specimens. Results suggested that aberrations of the p53 gene were not correlated with the malignancy of some types of brain tumors such as anaplastic astrocytoma and glioblastoma, contrary to previous observations on colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1886708

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  The p53 status in juvenile chronic arthritis and rheumatoid arthritis.

Authors:  H Taubert; B Thamm; A Meye; F Bartel; A K Rost; D Heidenreich; V John; J Brandt; M Bache; P Würl; H Schmidt; D Riemann
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

Authors:  B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas.

Authors:  J H Kim; S H Lee; C H Rhee; S Y Park; J H Lee
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

4.  Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.

Authors:  Tomohiro Kawaguchi; Yukihiko Sonoda; Ichiyo Shibahara; Ryuta Saito; Masayuki Kanamori; Toshihiro Kumabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2016-07-11       Impact factor: 4.130

5.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

Authors:  H Haapasalo; J Isola; P Sallinen; H Kalimo; H Helin; I Rantala
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

6.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Alterations in tumour suppressor gene p53 in human gliomas from Indian patients.

Authors:  Poornima Phatak; S Kalai Selvi; T Divya; A S Hegde; Sridevi Hegde; Kumaravel Somasundaram
Journal:  J Biosci       Date:  2002-12       Impact factor: 1.826

8.  Low p53 protein expression in salivary gland tumours compared with lung carcinomas.

Authors:  Y Soini; D Kamel; K Nuorva; D P Lane; K Vähäkangas; P Pääkkö
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

9.  p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies.

Authors:  E Karamitopoulou; E Perentes; I Diamantis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 10.  Molecular biology of pediatric gliomas.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.